Candel Therapeutics
Develops viral immunotherapies for solid tumors through adenovirus and HSV platforms.
$13.07
After-hours close+0.01 (+0.08%)
At close$13.06(−5.02%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 59.27%43.43M sharesInsiders 7.23%5.30M sharesOther 33.50%24.54M shares
Shares outstanding 73.27M · Float 56.81M · 77.5% free float
Institutions13F, as of Mar 31, 2026
118 holders · 43.43M shares · 40 new positions · 82 increased · 20 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 10.99M | 15.00% | +2.75M | May 15, 2026 |
| RTW Investments, LP | 6.42M | 8.76% | +6.42Mnew | May 15, 2026 |
| Acorn Capital Advisors, LLC | 3.50M | 4.77% | +917.4K | May 15, 2026 |
| BlackRock, Inc. | 3.11M | 4.24% | +247.4K | May 13, 2026 |
| Saturn V Capital Management LLC | 2.90M | 3.95% | +2.90Mnew | May 15, 2026 |
| Portolan Capital Management, LLC | 2.89M | 3.95% | +1.20M | May 15, 2026 |
| Vanguard Capital Management LLC | 2.46M | 3.36% | +2.46Mnew | May 15, 2026 |
| Vestal Point Capital, LP | 1.13M | 1.54% | +1.13Mnew | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 9.30% | 3.92M | 13G | Feb 7, 2025 ↗ |
| RTW Investments, LP | 8.80% | 6.42M | 13G | May 15, 2026 ↗ |
| Paul B Manningincl. The Paul B. Manning Revocable Trust dated May 10, 2000, BKB Growth Investments, LLC | 7.90% | 5.79M | 13D | Mar 18, 2026 ↗ |
| BlackRock, Inc. | 6.60% | 4.83M | 13G | Jul 27, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Paul B. Manning | director | 4.44M | 6.07% | Feb 26, 2026 |
| Paul Peter Tak | director, officer: Chief Executive Officer | 268.6K | 0.37% | Jun 26, 2025 |
| Christopher Martell | director | 263.3K | 0.36% | Jun 26, 2025 |
| Francesca Barone | officer: Chief Scientific Officer | 77.4K | 0.11% | Jul 1, 2026 |
| Seshu Tyagarajan | officer: Chief Technology Officer | 76.9K | 0.10% | Aug 19, 2026 |
| Joseph C. Papa | director | 64.2K | 0.09% | Jun 26, 2025 |
| William Garrett Nichols | officer: Chief Medical Officer | 52.5K | 0.07% | Jul 30, 2025 |
| Charles Schoch | officer: Chief Financial Officer | 43.4K | 0.06% | Jun 26, 2025 |
| Gary J. Nabel | director | 5.4K | 0.01% | Jun 26, 2025 |
| Nicoletta Loggia | director | 2.1K | 0.00% | Jun 26, 2025 |
8 people have not refiled in the last 18 months (2.44M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Seshu Tyagarajanofficer: Chief Technology Officer | Sale | 7,000 | $12.00 | 76,865 |
| Jun 29, 2026 | Seshu Tyagarajanofficer: Chief Technology Officer | Sale | 7,000 | $10.02 | 83,865 |
| Jun 29, 2026 | Francesca Baroneofficer: Chief Scientific Officer | Sale | 23,447 | $10.06 | 77,362 |
| Feb 23, 2026 | Paul B. Manningdirector | Purchase | 550,458 | $5.45 | 2,763,527 |
CongressHouse and Senate disclosures
Not reported.